You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: KINETIC CERAMICS, LLC Topic: NINR
DESCRIPTION (provided by applicant): Congenital cardiovascular defects, specifically single ventricle abnormalities, constitute the most common cause of death among infants born with birth defects. Even after surgically rerouting the single ventricle circulation via the Fontan procedure, the circulation in these patients relies on blood flowing passively through the lungs. Thus, this group of pati ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: NOTA Laboratories, Inc. Topic: NHLBI
ABSTRACTTherapeutic use of gas phase nitric oxideNOhas several important applications in medicineSince its first medical application more thanyears agoinhaled nitric oxideINOhas become a mainstay of intensive care for lung failure patientsAs a pulmonary vasodilatorINO is essential in neonatologylung transplantationand pulmonary hypertensionAs an inhaled antiseptic agentNO has been proposed in the ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: AURITEC PHARMACEUTICALS, INC. Topic: NIAID
DESCRIPTION (provided by applicant): The broad long-term of this project is to develop methods for evaluation of adherence to intravaginal microbicide therapy for the prevention of HIV transmission. Correct determination of adherence to preventative therapies in clinical trials is essential to accurate evaluation of efficacy. A better understanding of the true adherence to a preventative therapy w ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinomaSBC: Avenzoar Pharmaceuticals, Inc. Topic: 102
ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: BEAM Diagnostics, Inc. Topic: 41
PROJECT SUMMARY Fatal overdose from opioid misuse is one of the most pressing issues affecting the modern worldAs one of the nation s leading preventable causes of deatha critical line of defense against opioid use disorderOUDmust be standardized screening provided by the patient s primary care physicianpsychiatristand or counselorStandardized screening methods for opioidshoweverare simply inferio ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: TRICORDER ARRAY TECHNOLOGIES LLC Topic: 100
PROJECT SUMMARY The for profit small business concernTricorder Array Technologies LLCwill developin partnership with the University of Alabama at BirminghamSIDECAReSensing and Integrating Data for Environmental Conditions in Animal ResearchThis device will automate collection of relevant data that will enhance consistency in animal models used to study human health treatment researchOur innovative ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: SOLUBLE THERAPEUTICS, INC Topic: NIGMS
DESCRIPTION (provided by applicant): This proposal involves the development and validation of a novel approach to improve and accelerate the discovery of biopharmaceuticals (i.e. vaccines, monoclonal antibodies and other therapeutic proteins). Biopharmaceuticals are used to treat a variety of infectious and chronic diseases. The proposed research is intended to establish a new paradigm for rapidly ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.SBC: EARNANO LLC Topic: NICHD
Otitis media is a world wide disease primarily affecting the pediatric population under the age ofyearsIt is the most common reason for pediatric care visits and antibiotic therapyOver prescription and poorcompliance have led to a reduced susceptibility of bacteria to antibiotics andconsequentiallyto recurrent and chronic ear diseasesClearlythere is a compelling need to investigate alternative the ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: SERPLUS TECHNOLOGY LLC Topic: 200
The number of people with diabetes worldwide is predicted to increase frommillion intomillion inThe health care costs of treating the disease account forof the global health expenditure and continue to be a huge economic burdenIDF World AtlasTypediabetes mellitusT DMconstitutesof the disease burdenIt is an autoimmune diseasethought to be triggered by genetic or environmental factors in early child ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOCREDE INC. Topic: NIDDK
DESCRIPTION (provided by applicant): We propose a novel and price competitive Tunneled Dialysis Catheter (TDC) made from a proprietary polymeric formulation to effectively reduce TDC dysfunction via long-term nitric oxide (NO) release, particularly duringthe period of AVF maturation in incident hemodialysis and TDC dependent patients. Preliminary studies with polymer materials used to prepare exis ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health